Sun Is Not Walking Away From US Zubsolv Defeat
Indian Firm Lodges Appeal Following Comprehensive Ruling In New Jersey
Sun is looking to reignite Orexo’s legal headaches over its key Zubsolv opioid dependence treatment, following the Indian firm’s defeat in patent-litigation proceedings last month.
You may also be interested in...
Japanese originator Takeda has agreed to settle two-year-old anticompetitive claims lodged by wholesalers in the US that it conspired with several generics manufacturers to maintain supracompetitive pricing for its Colcrys branded treatment for gout.
European biosimilars specialist mAbxience will hand several of its biosimilars over to the global commercialization expertise of Abbott under a new agreement signed between the firms.
The FTC’s proposed consent order allowing Amgen to move ahead with its mammoth takeover of Horizon includes an interesting stipulation for industry – one involving biosimilars.